David Gamm, professor of ophthalmology and visual sciences, and postdoctoral researcher Celia Bisbach have developed a new therapy for retinal diseases that works by eliminating VEGF – a protein that triggers abnormal blood vessel growth in the eye – precisely at the site of disease. This highly targeted approach requires fewer injections than current therapies, avoids damage to healthy tissue, and could improve outcomes for patients with macular degeneration and other vision-threatening conditions.